Journals / Türk Oftalmoloji Dergisi / 2010 / Cilt: 40 - Sayı: 2

Treatment approach to autosomal recessive dystrophic epidermolysis bullosa

Otozomal resesif distrofik epidermolizis büllozada yaklaşım

Pages
107–112
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Discussion: According to our cases, alternative treatments such as amniotic membrane transplantation to treat symblepharon, and topical bevacizumab and autologous serum in intractable vascularization and opacity can be considered in cases of EB.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To present the treatment approach to ocular complications in two cases with autosomal recessive dystrophic epidermolysis bullosa (EB) and to review the literature.
📊
Key Findings & Data:Material and Method: Two teenage girls with EB, one with symblepharon (case 1) and the other with corneal opacity and vascularization (case 2) presented to our clinic.
💡
Conclusion & Impact:Discussion: According to our cases, alternative treatments such as amniotic membrane transplantation to treat symblepharon, and topical bevacizumab and autologous serum in intractable vascularization and opacity can be considered in cases of EB.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: To present the treatment approach to ocular complications in two cases with autosomal recessive dystrophic epidermolysis bullosa (EB) and to review the literature. Material and Method: Two teenage girls with EB, one with symblepharon (case 1) and the other with corneal opacity and vascularization (case 2) presented to our clinic. Case 1 had symblepharon, extending from the left upper eyelid to the superotemporal cornea, restricting the globe movements. During surgery, symblepharon lysis and lamellar keratectomy were followed by amniotic membrane transplantation to cover the cornea and palpebral conjunctiva. At presentation, case 2 was using artificial tears and topical cyclosporin A. The right eye had visual acuity of counting fingers, and opacity with superficial and deep vascularization in the lower third of the cornea. Topical bevacizumab and autologous serum were added to her treatment. Results: In Case 1, 63 months after surgery the eyelid margin was smooth and the eye was fully mobile. A mild symblepharon of the temporal conjunctiva in both eyes was present. Stromal thinning, superficial vascularization and opacification were significant in the temporal cornea. During the 8-month follow-up period of case 2, the visual acuity increased to 20/50. Slit-lamp examination showed a decrease in corneal opacity and vascularization. Discussion: According to our cases, alternative treatments such as amniotic membrane transplantation to treat symblepharon, and topical bevacizumab and autologous serum in intractable vascularization and opacity can be considered in cases of EB.

Özet

Amaç: Otozomal resesif geçişli distrofik tip epidermolizis bülloza tanısı almış iki hastada oküler komplikasyonlara tedavi yaklaşımını sunmak ve literatürü gözden geçirmek. Gereç ve Yöntem: Birinde semblefaron (Olgu 1) ve diğerinde korneada kesafet ve vaskülarizasyon (Olgu 2) gelişmiş epidermolizis bülloza tanılı iki genç kız kliniğimize başvurdu. Olgu 1’de göz küresinin hareketlerini kısıtlayan sol üst kapaktan üst temporal korneaya uzanan semblefaron mevcuttu. Semblefaron cerrahi olarak açıldı. Lamellar keratektomiyi kornea ve palpebral konjonktivayı kaplayan amnion membran transplantasyonu takip etti. Olgu 2 başvurduğunda suni gözyaşı ve topikal siklosporin kullanıyordu. Sağ gözde görme parmak sayma düzeyindeydi ve üçte bir alt korneada kesafet beraberinde yüzeyel ve derin vaskülarizasyon mevcuttu. Olgunun tedavisine topikal bevasizumab ve otolog serum eklendi. Sonuçlar: Olgu 1’de 63 ay sonra kapak kenarı düzgündü ve göz hareketleri serbestti. Her iki gözde temporal konjonktivada hafif semblefaron mevcuttu. Temporal kornea stromasında incelme, yüzeyel vaskülarizasyon ve kesafet belirgindi. Olgu 2’nin 8 aylık takibinde görme 0,4 düzeyine yükseldi. Biyomikroskop ile korneadaki kesafet ve vaskülarizasyonda azalma görüldü. Tartışma: Olgularımıza dayanarak epidermolizis büllozalı olgularda semblefaron varlığında amnion membranı transplantasyonu, diğer tedavilere cevap vermeyen kornea kesafeti ve vaskülarizasyon mevcudiyetinde de topikal bevasizumab ve otolog serum alternatif tedavi olarak düşünülebilir.

🔖

Cite This Article

AKOVA, Y. A., OTO, S., YAYCIOĞLU, R. A., KAYA, F. S. (2022). Treatment approach to autosomal recessive dystrophic epidermolysis bullosa. Türk Oftalmoloji Dergisi, Cilt: 40 - Sayı: 2, 107–112. https://ajindex.com/articles/638427

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. McDonnell PJ, Spalton DJ. The ocular signs and complications of epidemolysis bullosa. J R Soc Med. 1988;81:576-8
  2. Gans LA. Eye lesions of epidermolysis bullosa. Clinical features, management, and prognosis. Arch Dermatol. 1988;124:762-4
  3. Fine JD, Johnson LB, Weiner M, Stein A, Cash S, Deleoz J, et al. Eye involvement in inherited epidermolysis bullosa: experience of the National Epidermolysis Bullosa Registry. Am J Ophthalmol. 2004;138:254-62
  4. Destro M, Wallow IH, Brightbill FS. Recessive dystrophic epidermolysis bullosa. Arch Ophthalmol. 1987;105:1248-52
  5. Kim J, Tseng SC. Transplantation of preserved human amniotic membrane for surface reconstruction in severely damaged rabbit corneas. Cornea. 1995;14:473-84
  6. Lin AN, Murphy F, Brodie SE, Carter DM. Review of ophthalmic findings in 204 patients with epidermolysis bullosa. Am J Ophthalmol. 1994;118:384-90
  7. Tong L, Hodgkins PR, Denyer J, Brosnahan D, Harper J, Russell-Eggitt I, et al. The eye in epidermolysis bullosa. Br J Ophthalmol. 1999;83:323-6
  8. Lazzaro DR, Kwon IS. Epidermolysis bullosa in a child. CLAO J. 2002;28:75-6
  9. Tseng SCG, Prabhasawat P, Lee SH. Amniotic membrane transplantation for conjunctival surface reconstruction. Am J Ophthalmol. 1997;124:765-74
  10. Shimmura S, Shimazaki J, Ohashi Y, Tsubota K. Antiinflammatory effects of amniotic membrane transplantation in ocular surface disorders. Cornea. 2001;20:408-13
  11. Altan Yaycıoğlu R, Akova YA. Amnion membran transplantasyonunun oftalmolojide yeri. T Klin Oftalmoloji. 2003;12:227-36
  12. Katırcıoğlu Y, Budak K, Şalvarlı S, Duman S. Semblefaron olgularında konjonktiva yüzey rekonstrüksiyonunda amnion membran transplantasyonu. T Klin Oftalmoloji. 2002;11:57-61
  13. Solomon A, Espana EM, Tseng SCG. Amniotic memebrane transplantation for reconstruction of the conjunctival fornices. Ophthalmology. 2003;110:93-100
  14. Martinez Pardo ME, Reyes Frias ML, Ramos Duron LE, Gutierrez Salgado E, Gomez JC, Marin MA, et al. Clinical applications of amniotic membranes on a patient with epidermolysis bullosa. Ann Transplant. 1999;4:68-73
  15. Spraul CW, Buchwald HJ, Lang GK, Lang GE. Recurrent corneal ulcer in a patient with Crohn's disease associated with epidermolysis bullosa acquisita. Klin Monatsbl Augenheilkd. 2003;220:423-6
  16. Altan-Yaycıoglu R, Akova YA, Oto S. Amniotic membrane transplantation for treatment of symblepharon in a patient with recessive dystrophic epidermolysis bullosa. Cornea. 1006;25:971-3
  17. Matsumoto Y,